Search This Blog

Saturday, September 8, 2018

REIT-owned post-acute providers attractive to private equity investors

Post-acute care providers are attracting interest from private equity firms as potentially lucrative long-term investment plays, while real estate investment trusts pull away from the slumping healthcare segment.
Private equity firms have traditionally stayed away from the healthcare provider space, but several factors, such as the rapidly aging baby boomer population, are attracting them to the industry.
And real estate investment trusts, which have long been the major players in post-acute facility ownership, are willingly selling their assets to the equity firms as they fail to get a return on investment from struggling skilled-nursing facilities and senior housing operators.
“When you think about private equity funds, their objective is to invest in the long term—they are looking at healthcare real estate as another bucket to invest in,” and at depressed values, post-acute looks attractive to more patient investors, said Britton Costa, director in Fitch’s corporates group and author of a recent report describing the trend.
Some of the most recent large deals in the sector support that belief. In April 2017, the Blackstone Group acquired 26 properties owned by Senior Lifestyle from the REIT Welltower for $745 million. Then in October 2017, Kindred Healthcare, which has several REIT agreements, sold its skilled-nursing facility arm to BlueMountain Capital Management for $700 million.
The firms are lured to invest in post-acute properties even as the providers struggle financially. Post-acute providers have been hit by the transition to value-based care by hospitals. Hospitals, ankle deep in value-based reimbursement, are becoming more averse to discharging patients in those facilities for quality reasons if sending the patient home is at all an option.
Moreover, SNFs are vulnerable to unpredictable and low reimbursement from Medicare and Medicaid when both programs are trying to cut spending.
At the same time, senior housing facilities, which are typically paid through personal income, have suffered from low occupancy. The senior housing space has exploded in recent years to anticipate the retirement boom, but the bulk of the boomers haven’t entered retirement yet. “We are simply at a point in time where there is a mismatch; the supply came before the country needed it,” Costa said. The demand will eventually meet the supply as the silver tsunami continues to break, he said.
Any rebound that comes won’t be quick enough for REIT owners of post-acute facilities. The quarterly performance pressure on REITs, which are generally publicly traded, is leading them to trim back on their healthcare exposure. “Right out of the gate, REITs have to generate cash flow effectively,” said Steven Shill, assurance partner and national leader of the BDO Center for Healthcare Excellence & Innovation.
Many of the REIT-owned healthcare properties were bought at competitively high prices with borrowed money, meaning they may have big paper losses. For instance, the REIT Welltower fell short of earnings expectations by more than half in the second quarter, reporting $0.41 earnings per share, missing estimates of $0.99 earnings per share.
Welltower executives, while not making a forecast, say they think that values may be roughly near the bottom. That scenario is ideal for greater involvement by private equity firms, which usually have long-term plans for new assets and don’t expect returns until five or seven years after deals close. To that end, the private equity firms are betting the post-acute space will end up being a lucrative investment in the future
“They are looking at the aging demographics and the increasing incentives for care to occur in lower-cost settings, and how that should provide fairly durable rental income over the long-term,” Costa said.
Kevin Brown, a REIT equity analyst for Morningstar, also is expecting a rebound in values, even for the REITs themselves. “The healthcare REITs have traded off in 2018 due to supply issues impacting senior housing operations in the short term, but there is evidence that supply is decreasing, and we expect there to be a significant demand wave positively impacting the sector over the next decade,” Brown recently wrote.
The senior housing space is still more attractive to private equity firms than SNFs, however, Shill said. Unlike SNFs, senior housing facilities don’t have to worry about the unpredictability associated with changing Medicare reimbursement rates along with the transition to value-based care.
“There is a bigger interest in senior housing,” Shill said.
There are private investors buying SNFs from REITs, but they usually also take over the operations so they have the ability to be innovative and fix issues, said Jason Dopoulos, senior managing director with financial advisory firm Lancaster Pollard.
“Private equity wants to own the operator and fix the return hurdles,” which even for SNFs is not insurmountable, he said.

Grifols Gains FDA OK for Anti-viral Med


Grifols, a global biotherapeutics company with major operations in North Carolina, has received approval from the U.S. Food and Drug Administration for a new formulation of GamaSTAN, its medicine for treating patients who’ve been exposed to the hepatitis A or measles viruses.
GamaSTAN is the only immune globulin product on the U.S. market approved for post- exposure protection against the two viruses. It is now available to healthcare providers across the country, the company said in a news release.
“This advancement in the GamaSTAN formulation marks an important milestone in Grifols’ ongoing R&D efforts, and we are confident that it will continue to be an important treatment option for healthcare providers,” said Bill Zabel, president of the company’s North America sales and commercial operations.
The product’s approval and roll-out come amid a national resurgence of hepatitis A, a contagious liver infection, and measles, a contagious infection in young children that had been nearly eradicated through vaccinations.
“Immune globulins such as GamaSTAN have been a valuable treatment option for many decades because they offer immediate and rapid protection with antibodies that fight infection,” said Stephen Scholand, M.D., an infectious disease specialist at MidState Medical Center in Meriden, Conn.
When administered within two weeks after exposure to the hepatitis A virus, immune globulin is 80 to 90 percent effective in preventing infection, according to the U.S. Centers for Disease Control.
In contrast, vaccinations – while still a valuable option – may not take effect for several weeks because the immune system needs time to produce antibodies against the viruses, Scholand said.
The CDC recommends immune globulin treatment after exposure to the hepatitis A virus in people who are immunocompromised, under 1 year old or over 40 years old, or who have cancer, chronic liver disease or kidney disease.

Thermo Fisher: Complete Cannabis Testing for Canadian Single Source


With the updates to Canada’s cannabis laws set for implementation in October 2018, scientists operating within this highly regulated, growing market can now access an end-to-end analytical solution that aligns with the testing standards set by Health Canada.
Thermo Fisher Scientific is supporting regulatory laboratories, contract research organizations and licensed dealers, producers and suppliers across this emerging sector with a diverse and comprehensive product portfolio that offers complete workflows, from sample preparation to analytical methods, for the analysis of cannabis matrices to the testing standards set by Health Canada. Thermo Fisher will showcase its consumables, instruments and software that form these workflows at Grow Up Conference and Expo 2018, on September 7-8, at booth #311, Scotiabank Convention Centre, Niagara Falls, ON, Canada.
‘Thermo Fisher Scientific is supporting solutions for compliance with cannabis testing regulations in Canada by providing complete workflows and technologies to equip and supply licensed Canadian analytical labs with everything they need to start or scale laboratory operations and produce reliable results,’ said Dan Shine, president, analytical instruments, Thermo Fisher. ‘The workflows will enable the end-user to collect data, proof statements and application notes leveraged from key private, fully-licensed laboratories in Canada that are focused on development, validation, accreditation and sample preparation.’
‘We believe that, ultimately, the goal of government safety standards and the licensed producer community is to ensure Canadian cannabis products are free from potentially dangerous contaminants,’ said Randy Rowe, President of Grow Up Conference and Expo. ‘By adopting proven technologies and approaches from other industries like the food testing arena, Canada’s emerging cannabis industry has a path forward and the tools to confirm that every sample analyzed meets regulated safety standards and is suitable for the Canadian cannabis market.’
The scope of Thermo Fisher’s cannabis workflows allows scientists to not only perform tests for tetrahydrocannabinol contentmicrobial contaminants and disintegration, but also cannabinoid profilingnutritional information and water. Thermo Fisher’s cannabis testing solutions can be enhanced when combined with cloud-connected laboratory information management system (LIMS), which support information management and regulatory compliance across small, growing and established operations.
In addition to the Grow Up Conference and Expo, Thermo Fisher will host a complimentary educational ‘Cannabis Testing One-Stop Analytical Solutions Seminar Series ‘ across Canada, October 9-18, with the first seminar in Vancouver (Four Points by Sheraton Vancouver Airport). The seminar series will provide information to scientists establishing new cannabis testing laboratory or scaling-up operations. Each seminar will cover:
  • Health Canada regulation updates
  • Targeted and non-targeted pesticide analysis
  • Sample preparation tips for improving results
  • Fast and accurate heavy metal analysis to ppb levels
  • Rapid mycotoxin analysis
  • Cannabis potency testing
  • Analytical software and cloud LIMS solutions
For more information on Thermo Fisher’s complete cannabis testing solutions for the Canadian Market, please visit www.thermofisher.com/CannabisTesting.

Unilever confronts the ‘chairdrobe’ as consumers rethink laundry


On any given day, the chair in Raven Rose’s Ewing, New Jersey, bedroom might be draped with shirts, pants or pyjamas.

“It depends on how exhausted from work I am and if I plan to wear them again,” said the 35-year-old retail clerk.
Marketers at consumer goods giant Unilever are calling it the “chairdrobe” – the heap of lightly worn clothes that often ends up crumpling one’s go-to garments.
It’s a familiar sight in the bedrooms of some 60 percent of millennials – 22- to 37-year-olds earning more than a quarter of the world’s income – who approach laundry differently from other age groups, Unilever’s market research shows.
That’s a pain point for the company, maker of Omo, the world’s second-biggest detergent after Procter & Gamble’s Tide. Tide, also known as Ariel, has 14.3 percent of the global laundry care market versus Omo’s 5.2 percent, Euromonitor International says.
For decades, Unilever and P&G have pitched new and improved laundry detergents and fabric softeners, primarily to women using washing machines. But millennials are less loyal to traditional brands and have new demands, including that products save time and be environmentally sustainable.
Many, like 36-year-old Olivia Tusinski, want to spend as little time as possible on laundry. Plus, washing too often wears your clothes out faster, she says.
“I don’t like to waste water or energy,” said Tusinski, a government employee in London.
P&G tested a line to woo the wash-weary a decade ago after discovering how common re-wearing clothes was. The Swash brand was parlayed into a $499 de-wrinkling appliance in partnership with Whirlpool but two products made it to market as Downy Wrinkle Releaser spray and Tide Stain Pen.
Now, Unilever is having a go with Day 2, an aerosol spray that went on sale online only last week that it says refreshes, reshapes and dewrinkles clothes on the chairdrobe, using technology like fabric-stiffening molecules.
There are versions for denim and delicates, in addition to the original. Denim jeans are by far the most reworn garment, Unilever says. “That’s a high pride point for a lot of millennials, you know, ensuring that their denim is as pristine as possible,” said Day 2’s co-founder and marketing head Nathan Olivieri.
Denim aficionados have warned for years against washing jeans. Levi Strauss CEO Chip Bergh, a 28-year veteran of P&G, told a conference in 2014 that the jeans he was wearing that day were a year old and had never been washed.
LIKE A START-UP
Unilever’s home care president Kees Kruythoff calls catering to millennials’ mindset a way of “future-proofing” the portfolio. In addition to Day 2 in the United Kingdom, Unilever is testing a portion-controlled detergent in the Netherlands called Less. Both projects have been structured as if the developers were small and agile start-ups, not a multinational.
The global laundry detergent market is expected to reach $205.2 billion by 2025, up from $133.3 billion in 2016, according to Grand View Research, which predicts 4.9 percent annual growth fuelled by the rising penetration of washing machines in developing countries.
In more developed markets, growth is helped by eco-friendly brands like Seventh Generation, now owned by Unilever, and Method, Grand View said.
These upstart brands, which boast fewer chemicals and packaging with recycled plastic, are part of the wave of disruption that earlier slammed food and personal care and has finally shaken up home care.
Laundry leaders P&G, Unilever and Henkel are aiming to save consumers time with pre-measured or all-in-one offerings. Meanwhile, start-up subscription brands deliver soap to consumers’ homes, while new mobile apps offer laundry services on demand.
Unilever’s detergent Skip has partnered in Paris with the mobile app Cowash to connect people with neighbours willing to wash and iron their laundry for a fee.
Cowash says about 80 percent of its customers have washing machines and wash some of their clothes, but use the service to avoid time-consuming items like shirts that need ironing.
“They don’t do it because they don’t have washing machines, they do it because they don’t have time,” Cowash founder Adrien Hugon said.
Indeed, the project brief Unilever handed down to Olivieri some 10 months ago was to create a product that would give millennials more confidence to rewear worn clothes, since there was nothing on the market that explicitly targeted the issue and addressed smell, wrinkles and shape, the 25-year-old told Reuters.
While P&G’s Febreze spray can be used to remove odours from clothes, for example, it more often focuses on hard-to-clean fabrics in the home or car such as upholstery and curtains.
Over the course of one month last autumn, Olivieri’s ten-person team developed the brand away from corporate headquarters in a rented house in a village outside Liverpool, frequently inviting consumers in for real-time feedback.
The project is representative of how Unilever is approaching new brand development with research that engages consumers early in the process.
The premium all-in-one product is delivered in packaging meant to be attractive enough to be displayed in a bedroom, Olivieri said. It’s a proposition that was never going to be cheap: a 200-ml can that can treat 25 garments costs 7.50 pounds ($9.68), compared to the roughly 7 pounds it costs to buy enough of Unilever’s Persil Powercaps to wash 30 loads of laundry.
“We know the chairdrobe is a universal concept … but as we move into a modern age where we’re more time-poor than ever, that’s becoming an even more relevant consumer problem,” Olivieri said.

Frozen Dinners Make a Comeback


Frozen dinners are on a hot streak.
Sales of microwavable meals are rising at the fastest pace in a decade, drawing attention from food-company executives otherwise struggling with falling sales for well known but outdated brands.
“We believe this is not a blip,” said Sean Connolly, chief executive of Conagra Brands Inc., maker of Healthy Choice, Banquet and Marie Callender’s frozen meals. “For the first time in a generation, this space is starting to be modernized again.”
Sales of frozen entrees rose 5.7% over the year ended July 15, according to market-research firm Spins, after annual growth of 0.6% and 1.5% the previous two years. The latest bump outpaces the 2% rise in overall packaged-food sales and marks a change from several years of diminishing sales in frozen meals earlier this decade.
Conagra, Nestlé SA and Kraft Heinz Co. are spending millions of dollars to freshen up frozen brands, introduce new ones and expand manufacturing capacity.
Karrin Childs, a 37-year-old accountant in Akron, Ohio, got past her aversion to bland frozen meals after trying Nestlé’s new Lean Cuisine dishes, such as butternut squash ravioli, in distinctive black packaging.
“It’s always good to have one in your freezer in case of an emergency,” she said.
Efforts to cut salt, sugar and other less healthful ingredients from ready-made meals appear to be resonating with customers who like their convenience.
Sales of other frozen foods such as vegetables and pizza have also improved recently. Overall frozen-food sales rose 3% in the year ended July 15, according to Spins.
The pickup in sales of frozen meals comes as companies have shaken up both the ingredients and the packaging used.
Last year Nestlé introduced Wildscape, a brand of frozen foods made with ingredients like honey-bourbon brisket and cauliflower in gochujang sauce. Wildscape meals — like chimichurri chicken with roasted peppers, red potatoes, farro, aji amarillo purée and almonds — are packaged in semitransparent plastic jars inspired by ice-cream containers.
“Historically it’s been about comfort food; now it’s about modern American cuisine,” said Jeff Hamilton, head of Nestlé’s U.S. foods division, which sells a dozen frozen-meal brands including Stouffer’s, Hot Pockets and DiGiorno.
Conagra put its new Healthy Choice Power Bowls in plant-based, compostable packaging to appeal to consumers who said they didn’t like microwaving plastic. Healthy Choice sales rose about 20% in the fiscal fourth quarter ended in May, bringing the brand to $400 million in retail sales for the fiscal year.
Mr. Connolly said that success encouraged Conagra to buy Pinnacle Foods Inc. this year for about $8.2 billion, adding Birds Eye, Evol Foods and other frozen brands to its product line. The deal is expected to close by year-end.
Modern frozen food dates to Clarence Birdseye, who in the 1920s invented a way to flash-freeze fish, building on an Inuit technique he learned in Canada. That kept food from spoiling without losing as much flavor or nutritional value as slow freezing or canning.
In the 1950s, Swanson’s TV dinners and Totino’s frozen pizzas changed the family dinner ritual. In the 1980s, food makers introduced low-fat and low-sodium brands to match diet trends. Most brands hadn’t changed much since then until recently, executives say.
While Healthy Choice and Lean Cuisine fell out of favor, higher-end meals from new brands such as Evol and Lyfe Kitchen drew customers back to the freezer cases. That spurred bigger companies to reinvest in frozen.
“It’s a rare feat that you see a legacy business that’s been around since the ’80s that was really quite sluggish come back to life,” Mr. Connolly said of Healthy Choice.
Similarly, Nestlé has recast Lean Cuisine as a more generally healthful brand rather than one focused on low-calorie meals.
“It took us a while to understand and adapt,” Mr. Hamilton said.
The company has been working to turn around its frozen-food business. Three years ago, the Switzerland-based company opened a $50 million research and development center for frozen foods in Solon, Ohio.
Nestlé chefs and developers there test new dishes in 60 microwaves from around the world, tweaking recommended cooking times to deliver the best flavor. Meals are also tested on a vibrating table and dropped to make sure the packaging won’t shatter or bend.
Kraft Heinz, meanwhile, has revamped its Weight Watchers meals with a new line called SmartMade that highlights “real ingredients you can pronounce” in dishes like white-wine chicken and couscous with roasted vegetables.
In 2017, SmartMade and a new, indulgent frozen meal brand by Kraft Heinz called Devour generated more than $100 million in retail sales. The brands drove growth in Kraft Heinz’s frozen-meal business, which until then, had spent “the better part of a decade in decline,” the company said.

Hepatitis B and Hepatitis D


Hepatitis B is a life-threatening liver infection that is caused by the hepatitis B virus, whereas, hepatitis D infection only occurs in people who are infected with the hepatitis B virus. It replicates autonomously within hepatocytes, but requires hepatitis B surface antigen for proliferation.
Hepatitis D and Hepatitis B
Hepatitis D and Hepatitis B

Common Symptoms

Majority of carriers of hepatitis B virus remain asymptomatic during the initial phase of acute infection, albeit some suffer from acute symptoms which prevail for few weeks.
Like hepatitis B virus, most of the people with hepatitis D virus infection also do not show any symptoms for long. Others may show an exacerbation of their pre-existing hepatitis B symptoms.
Common symptoms include weakness, fatigue, nausea, fever, joint pain, abdominal pain, yellowing of eyes or skin (jaundice), vomiting, dark urine etc.

Transmission

The incubation period of hepatitis D is approximately 14 to 60 days, while for hepatitis B it is approximately 75 days, but may also vary from 30 to 180 days.
Both hepatitis D and hepatitis B viruses can spread via blood transfusion, saliva, needlestick injury, intravenous drug supplies, or semen and vaginal secretions.Sexual transmission can occur in unvaccinated homosexual men, heterosexual persons with multiple sex partners, or through sex workers.
Hepatitis D virus can also be transmitted from mother to child, though very rarely. However, pregnant women with hepatitis B can transmit the virus to their babies at the time of birth.

Coexistence of Hepatitis B and Hepatitis D

Hepatitis B and Hepatitis D infections can occur together as a coinfection or a superinfection.
Coinfection: A coinfection takes placedue to simultaneous infection with both hepatitis D and hepatitis B viruses. This results in acute hepatitis D or hepatitis B. Coinfections can give rise to fulminant hepatitis.
Usually, patients are able to recuperate from the acute hepatitis D and hepatitis B infections, and the viruses head off. However, approximately 5% of the coinfected patients suffer from chronic infections which do not recover easily.
Superinfection: A superinfection takes place in the patients who are already infected with hepatitis B infection and further get infected with hepatitis D. The symptoms of a superinfection are usually acute and severe in nature.
A huge majority of the patients having a superinfection are incapable of combating hepatitis D virus infection, and consequently suffer from chronic hepatitis D. Hence, such patients can contract chronic hepatitis D and hepatitis B simultaneously.

Complications

Chronic hepatitis B and hepatitis D infections can result in serious complications, such as cirrhosis (scarring of the liver), liver cancer, liver failure, and other conditions like development of kidney disease or inflammation of blood vessels.

Management

Prevention of hepatitis D virus infection depends on the prevention of hepatitis B. In order to reduce the chances of infection, the hepatitis B vaccine should be administered prophylactically.
Besides vaccination having a safe sex, covering the open cuts, sores, or abrasions with waterproof dressings, and refraining from sharing intravenous needles or drug supplies protects the body against both HepatitisB and D infections.
There is no specific treatment for acute hepatitis B.
The most important focus of management should be at maintaining optimum nutrition and a healthy state. This also includes supplementing the fluid balance of the body by drinking sufficient quantities of water. Oral antiviral agentsare also employed for treating chronic hepatitis B infection.
At present, there is no vaccine available for hepatitis D infection. Hepatitis B vaccine can keep hepatitis D in check by preventing hepatitis B infection.
Currently, pegylated interferon is the sole approved class of medication that has proven beneficial in treating hepatitis D.

Further Reading

With big-name backing, startup eyes matching cancer patients, clinical trials


An ambitious startup aimed at connecting cancer patients with clinical trials launched on Thursday, one that is betting a smartphone app can help close the notorious gap between patients seeking experimental treatments and cancer centers ready to offer it.
Driver, as the company is called, will charge cancer patients $3,000 upfront plus a $20 monthly fee — all out of pocket — for a service that analyzes their tumor sample and their medical record. Driver uses that information to recommend options for both approved treatments and clinical trials as well as facilitate referrals via an app that patients can access on their phones.
The startup is being launched with backing from Hong Kong’s richest man, Li Ka-shing, and with the support of other high-profile figures, including Jennifer Doudna, the University of California, Berkeley, scientist, who sits on Driver’s board. More than 30 cancer centers in the U.S., China, and Singapore — including top hospitals like Stanford, Mayo, and Cleveland Clinic — have already signed up to give their clinicians access to another version of the app, so that they can help patients navigate treatment options.
The idea is to address one of the most frustrating problems in health care. Only about one-seventh of adult cancer patients who are eligible to enroll in clinical trials actually sign up. And at the world’s top cancer centers, many studies get shut down because they can’t enroll enough patients; some trials can’t enroll anyone at all.
But it remains to be seen whether Driver will be able to achieve its bold ambitions. Clinicians are already inundated with technology, and they’ll have to embrace yet another piece of software if Driver is to succeed.
It’s also not clear whether Driver will be able to make enough money to build a sustainable business: The company is trying to convince patients already burdened by the costs of their disease to pay for its service. (It’s also trying to persuade employers, insurers, and pension funds to pay to give their members access to another version of the app aimed at healthy people that gives tips about prevention and reminders to schedule screenings like a mammogram or a colonoscopy.)
Driver’s executives believe the hurdles are surmountable.
When it comes to the American health care system, “everyone has decided that the problem is cost … but at its core, we have a performance problem here,” said Driver CEO and co-founder Dr. William Polkinghorn, a radiation oncologist by training who was previously on the faculty of Memorial Sloan-Kettering Cancer Center.
“We want Driver for Clinic to become the Bloomberg terminal for every oncologist around the world,” Polkinghorn said.
As evidence of the company’s high-profile backing, Driver arranged to get the director of the National Cancer Institute and the head of clinical research at the prestigious Massachusetts General Hospital Cancer Center on the phone with STAT to speak to the broken marketplace for clinical trials and vouch for Driver’s potential to help fix it.
NCI Director Dr. Ned Sharpless spoke in positive terms about Driver, saying he was hopeful that the company’s product would help with the metric NCI cares most about: increasing the number of patients enrolling in trials being run by NCI and its designated cancer centers. But he told STAT that Driver “has one potential problem that concerns me, which is the potential to create disparities.” He added: “If there’s this access to better care because patients can pay an extra bit and get this double secret better treatment, then that would be bad for the majority of patients that couldn’t afford the extra treatment.”
(Sharpless said he was pleased, though, that Driver had anticipated this problem by creating a charitable arm.)
Driver is far from the first effort to better match patients to clinical trials.
There’s the government’s trial registry clinicaltrials.gov, as well as a cancer-specific search tool. Clinical researchers are mandated by federal law to register Phase 2 and Phase 3 clinical trials, but in practice, the sites have significant limitations for patients and clinicians trying to navigate clinical trial options. Some trials don’t get listed at all. Many get listed months after they begin enrolling patients, or remain listed after they’ve shut down. And even those trials that get listed promptly often don’t post crucial information about eligibility requirements.
Other startups, too, have tried to take on the problem. For example, Antidote.me, a clinical trial matching service backed by Merck’s venture capital arm, makes money by charging referral fees to drug companies for trials testing their drugs and charging licensing fees to hospitals and clinics to use their service.
Driver’s tack of charging patients directly is more unusual. The number of patients who’ve tried it since the app became available in April 2017 — the company was in “stealth mode” until Thursday — is in the hundreds, Polkinghorn said. Patients can pay to get access to Driver’s service with their own money or via a special campaign on the crowdfunding website GoFundMe that can be set up to send the funds directly to Driver.
Driver has used much of its funding to build its own automated machines — one in San Francisco and another in China — to analyze patients’ tumor samples, which Driver arranges to get shipped from the hospital where patients got their initial tumor biopsy. Driver’s machines analyze the genetics and other molecular characteristics of the tumor.
For each of the cancer centers Driver partnered with, the company uploaded the hospital’s internal registry of clinical trials into its system. It was an exhaustive process: The company started by scraping trials listed on clinicaltrials.gov, and filled in the substantial gaps by going into the hospitals themselves. “We would find their clinical trials on everything from whiteboards to Google Docs to Excel sheets,” Polkinghorn said.
Consider the existing process at the cancer center at Massachusetts General Hospital. Each group of oncologists focusing on a specific disease — for example, breast cancer — build a roster of trials that they rank based on promise. They compile the list in a working document, said Dr. Keith Flaherty, the medical oncologist who directs clinical research there.
Driver has uploaded the information in those working documents into its app and getting Mass General ready to soon start using it.
For support that its approach works, Driver points to a study it conducted looking at 21 patients with advanced prostate cancer enrolled in NCI trials. Driver’s method correctly predicted that 20 of them were “potentially eligible” for the trial they ultimately enrolled in. The company presented that data this spring at the annual meeting of the American Society of Clinical Oncology.
An early peek into how Driver’s product is being used can be found in its charitable arm, Driver for All. One of the projects that Driver is fully funding under the program has begun matching patients being treated at Howard University to clinical trials at NCI’s in-house cancer center in Bethesda, Md. Many of the patients involved are underrepresented in clinical research, such as African-American men.
Among them is Anthony Young, a 50-year-old landscaper from Washington, D.C. He was diagnosed 18 months ago with prostate cancer that’s now classified as high-risk stage 2, a point at which the cancer is curable and confined to the prostate but has a risk of spreading.
Howard oncologists have used Driver’s app to help Young narrow down his potential clinical trials options to three being run at NCI. He’s narrowed that down further to two options, because he prefers a study approach deploying radiation. He’s currently undergoing biopsies and scans that will help decide which clinical trial he’ll be able to enroll in.
“I want the best treatment possible for myself,” Young said, “and to get back to living my life.”